LCTX Stock Analysis: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.20
-0.01 (-0.83%)
▼
5d:
-7.69%
30d:
-15.49%
90d:
-38.46%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.20, which is considered oversold relative to its 30-day fair value range of $1.25 to $1.47.
Technical Outlook: Technically, LCTX is in a strong uptrend. The price is currently testing key support at $1.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+354.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LCTX is in a strong uptrend. The price is currently testing key support at $1.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+354.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.25 -
$1.47
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 354.5% below Wall St target ($5.50)
- CAUTION: Recommendation downgraded due to -7.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.25 -
$1.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.19
Resistance Level
$1.37
Current Trend
Strong Uptrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.44
Wall Street Target
$5.50
(+354.5%)
Revenue Growth (YoY)
14.8%
Share & Embed Analysis
Last updated: June 03, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian M Culley
BUY
15000 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
